RECURSION PHARMACEUTICALS, INC. (RXRX) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$116.80M*; Operating income -$134.97M; Depreciation and amortization $18.17M*.
- 2026-03-31: Basis Reported; EBITDA -$108.83M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$88.86M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$151.16M*; Operating income -$172.20M; Depreciation and amortization $21.04M*.
Complete source-backed ebitda history.
- Available history
- 2019-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$116.80M* | -$134.97M | $18.17M* | $7.67M | -1522.83%* | $44.00K* | -$105.95M* | $11.49M | $89.61M | (m) | -$1.00K |
|---|
| 2026-03-31 | Reported | -$108.83M | (m) | (m) | (m) | -1681.58% | $258.00K | -$81.10M | $12.49M | $87.90M | (m) | -$4.60M |
|---|
| 2025-12-31 | Reported | -$88.86M | (m) | (m) | (m) | -250.03% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$151.16M* | -$172.20M | $21.04M* | $5.17M | -2920.95%* | $243.00K* | -$117.36M* | $14.69M | $121.06M | (m) | $3.00K |
|---|
| 2025-06-30 | Reported | -$152.38M* | -$176.23M | $23.85M* | $19.22M | -792.69%* | $3.15M* | -$76.42M* | $20.16M | $128.64M | (m) | $0.00 |
|---|
| 2025-03-31 | Reported | -$172.04M | (m) | (m) | (m) | -1166.75% | $1.83M | -$131.96M | $21.83M | $129.63M | (m) | -$158.00K |
|---|
| 2024-12-31 | Reported | -$170.82M | (m) | (m) | (m) | -3757.52% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$91.16M* | -$98.35M | $7.20M* | $26.08M | -349.50%* | $4.56M* | -$59.23M* | $12.08M | $74.60M | (m) | $167.00K |
|---|
| 2024-06-30 | Reported | -$91.58M* | -$100.54M | $8.97M* | $14.42M | -635.19%* | $1.18M* | -$82.22M* | $9.20M | $73.93M | (m) | -$523.00K |
|---|
| 2024-03-31 | Reported | -$88.96M | (m) | (m) | (m) | -644.94% | $6.65M | -$102.30M | $11.17M | $67.56M | (m) | -$779.00K |
|---|
| 2023-12-31 | Reported | -$91.38M | (m) | (m) | (m) | -839.01% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$91.97M* | -$99.55M | $7.58M* | $10.53M | -873.18%* | $745.00K* | -$72.92M* | $10.88M | $70.01M | (m) | $0.00 |
|---|
| 2023-06-30 | Reported | -$76.17M* | -$81.72M | $5.54M* | $11.02M | -691.40%* | $3.97M* | -$67.47M* | $9.38M | $55.06M | (m) | $0.00 |
|---|
| 2023-03-31 | Reported | -$66.14M | (m) | (m) | (m) | -545.06% | $5.17M | -$73.32M | $12.45M | $46.68M | (m) | $0.00 |
|---|
| 2022-12-31 | Reported | -$57.77M | (m) | (m) | (m) | -422.40% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | -$59.58M* | -$62.57M | $2.99M* | $13.16M | -452.77%* | $8.26M* | -$54.54M* | $15.41M | $40.84M | (m) | $0.00 |
|---|
| 2022-06-30 | Reported | -$63.41M* | -$66.19M | $2.79M* | $7.67M | -826.23%* | $16.48M* | -$61.62M* | $14.23M | $38.44M | (m) | $0.00 |
|---|
| 2022-03-31 | Reported | -$53.21M | (m) | (m) | (m) | -997.82% | $4.34M | $77.39M | $7.80M | $32.44M | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | -$62.72M | (m) | (m) | (m) | -2476.27% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2021-09-30 | Reported | -$43.97M* | -$46.40M | $2.44M* | $2.53M | -1735.04%* | $9.71M* | -$33.05M* | $0.00 | $33.25M | (m) | $0.00 |
|---|
| 2021-06-30 | Reported | -$38.60M* | -$40.93M | $2.33M* | $2.55M | -1514.24%* | $6.21M* | -$33.65M* | $0.00 | $29.62M | (m) | $0.00 |
|---|
| 2021-03-31 | Reported | -$29.08M | (m) | (m) | (m) | -1135.13% | $19.42M | -$30.75M | $0.00 | $24.11M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | -$24.46M | (m) | (m) | (m) | -908.81% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2020-09-30 | Reported | -$21.62M* | -$22.47M | $857.00K* | $1.02M | -2108.98%* | $826.00K* | -$19.46M* | (m) | $16.54M | (m) | $0.00 |
|---|
| 2020-06-30 | Reported | -$17.19M* | -$18.22M | $1.02M* | $186.00K | -9243.55%* | $634.00K* | -$16.70M* | (m) | $13.24M | (m) | $0.00 |
|---|
| 2020-03-31 | Reported | -$17.41M | (m) | (m) | (m) | -29010.00% | $684.00K | -$17.82M | (m) | $12.84M | (m) | $0.00 |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$564.43M | (m) | (m) | (m) | -755.79% | $6.47M | -$371.81M | $70.95M | $475.27M | (m) | -$136.00K |
|---|
| 2024-12-31 | Reported | -$442.51M | (m) | (m) | (m) | -752.07% | $13.70M | -$359.17M | $45.24M | $314.42M | (m) | -$1.13M |
|---|
| 2023-12-31 | Reported | -$325.66M | (m) | (m) | (m) | -730.58% | $11.96M | -$287.78M | $42.59M | $241.23M | (m) | -$4.06M |
|---|
| 2022-12-31 | Reported | -$233.97M | (m) | (m) | (m) | -587.23% | $37.06M | -$83.52M | $48.27M | $155.70M | (m) | $0.00 |
|---|
| 2021-12-31 | Reported | -$174.37M | (m) | (m) | (m) | -1713.20% | $39.80M | -$158.61M | $0.00 | $135.27M | (m) | $0.00 |
|---|
| 2020-12-31 | Reported | -$80.67M | (m) | (m) | (m) | -2036.14% | $5.83M | -$45.40M | $0.00 | $63.32M | (m) | $0.00 |
|---|
| 2019-12-31 | Reported | -$59.95M | (m) | (m) | (m) | -2585.25% | $3.91M | -$57.04M | (m) | $45.81M | (m) | $0.00 |
|---|